Enlivex Therapeutics (NASDAQ:ENLV) Announces Earnings Results, Beats Estimates By $12.88 EPS

Enlivex Therapeutics (NASDAQ:ENLV) issued its quarterly earnings results on Wednesday. The company reported $12.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $12.88, FiscalAI reports.

Here are the key takeaways from Enlivex Therapeutics’ conference call:

• Enlivex reported $1.23 billion in net income and $25.48 EPS for 2025, which management says was driven primarily by market‑based revaluation of its prediction‑markets treasury (RAIN token).
• The company holds an exclusive option to acquire up to 275 billion RAIN tokens at $0.0033 (exercise window extended to Dec 31, 2027), announced a $21 million financing to buy 3 billion RAIN for $10 million, and issued a convertible note with a 90‑day non‑convertible period and a high conversion premium plus a board‑approved up to $20 million share repurchase program.
• FDA cleared an IND for a late‑stage Phase IIb trial of Allocetra in knee osteoarthritis, with 3‑ and 6‑month top‑line data expected in 2027 and the company framing Allocetra as a key clinical value driver.
• Results and valuation gains are concentrated in a nascent, volatile prediction‑markets token (RAIN), making the 2025 GAAP profits potentially non‑repeatable and leaving the company exposed to token market swings and continued public‑market NAV discounts.

Enlivex Therapeutics Price Performance

ENLV opened at $1.09 on Friday. The firm has a market capitalization of $258.75 million, a price-to-earnings ratio of -1.98 and a beta of 1.55. The company’s 50 day simple moving average is $1.10 and its two-hundred day simple moving average is $1.02. Enlivex Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.10.

Institutional Investors Weigh In On Enlivex Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ENLV. Jane Street Group LLC increased its stake in shares of Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock worth $52,000 after acquiring an additional 52,553 shares during the last quarter. Susquehanna International Group LLP purchased a new position in shares of Enlivex Therapeutics during the 3rd quarter worth $57,000. Renaissance Technologies LLC boosted its position in shares of Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after acquiring an additional 156,336 shares during the last quarter. HRT Financial LP grew its holdings in shares of Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after purchasing an additional 135,198 shares during the period. Finally, Invesco Ltd. purchased a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at about $43,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ENLV. Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. HC Wainwright lifted their price target on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $13.00.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.